Telomir Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3.27	0	0	0
Cash & Cash Equivalents	3.27	0	0	0
Cash Growth	230647.99%	-13.25%	-	-
Receivables	0.13	0.13	0	0
Other Current Assets	0.1	0.3	0.05	0
Total Current Assets	3.5	0.44	0.05	0
Other Long-Term Assets	0	4.34	0	0
Total Long-Term Assets	0	4.34	0	0
Total Assets	3.5	4.77	0.05	0
Accounts Payable	0.49	1.23	0.99	0.14
Current Debt	0	0.1	0	0
Total Current Liabilities	0.49	1.34	0.99	0.14
Total Liabilities	0.49	1.34	0.99	0.14
Total Debt	0	0.1	0	0
Retained Earnings	-20.32	-14.06	-0.99	-0.14
Shareholders' Equity	3.02	3.44	-0.94	-0.14
Net Cash / Debt	3.27	-0.1	0	0
Net Cash / Debt Growth	230647.99%	-	-	-
Net Cash Per Share	-	-0.00	0.00	-
Working Capital	3.02	-0.9	-0.94	-0.14
Book Value Per Share	0.11	0.13	-0.04	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).